|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Bladder Cancer | |||||
| Transitional Cell Bladder Cancer | |||||
| Urethra Cancer | |||||
| Ureter Cancer | |||||
| Renal Pelvis Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Pelvic Neoplasms | |||||
| Ureteral Neoplasms | |||||
| Urethral Neoplasms | |||||
| Urinary Bladder Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Ureteral Diseases | |||||
| Urethral Diseases | |||||
| Urinary Bladder Diseases | |||||
| Urogenital Neoplasms | |||||
| Urologic Diseases | |||||
| Urologic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| AZD4877 | |||||
| 5 | Sponsors listed in this trial | ||||
| AstraZeneca | |||||